Sirolimus
Rapamune · mTOR inhibitor
Proteinuria, cast nephropathy, delayed graft recovery.
Afinitor · Torisel · mTORi
mTOR inhibitor · approved 2009 · 8 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
Disrupt the podocyte's maintenance program and protein slips through.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Everolimus commonly causes all-grade proteinuria, with high-grade uncommon; mTOR-inhibitor proteinuria/FSGS is well described. Temsirolimus case-level only.Source: Vollenbröker et al., Am J Physiol Renal Physiol 2008; Letavernier et al., 2008
Develops over weeks to months of therapy.
Distilled from: “Weeks–months.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Proteinuria in 96% (44/46) of everolimus-treated first-line metastatic RCC patients (overall 81% across VEGF/mTOR agents), the great majority grade 1-2 and managed by continued monitoring; reflects mTOR-inhibitor podocyte/slit-diaphragm injury. High-grade (grade 3-4) proteinuria is uncommon.
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.
Tap a signature to trace where it strikes the nephron.
Glomerular Injury / Proteinuria strikes: Glomerulus.
Glomerular Injury / Proteinuria
Damage to the filtration barrier — podocyte injury, FSGS and protein leak from VEGF and mTOR blockade.
Everolimus and temsirolimus inhibit mTORC1 to block cell growth, proliferation and angiogenesis. Renal cell, neuroendocrine and breast cancer.
Class-level context for the major non-renal toxicities of the mTOR inhibitor class.
Pulmonary
Pneumonitis, ILD, effusions, hypertension
Endocrine
Thyroiditis, hypophysitis, diabetes
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
Immune / Infusion
CRS, infusion reactions, irAEs, anaphylaxis
5 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where mTOR Inhibitors sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Rapamune · mTOR inhibitor
Proteinuria, cast nephropathy, delayed graft recovery.
Tarceva · EGFR TKI
Rare minimal-change disease and AKI.
Torisel · mTOR inhibitor
Proteinuria and glomerular effects; less firmly quantified than everolimus.
Afinitor · mTOR inhibitor
Podocyte injury with proteinuria/FSGS; occasional thrombotic microangiopathy.
Eloxatin · Platinum agent
Least nephrotoxic platinum; rare immune hemolysis.
Boniva · Bisphosphonate
Lower renal risk than zoledronate.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to mTOR Inhibitors’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on mTOR Inhibitors; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 171 clinical records among all 244 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.